Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+

ConditionHealthy Aging

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age40-65

SponsorNutraceuticals Research Institute

About this trial

This study evaluates the subjective effects of injection administration of NR on healthy adult populations.

Eligibility criteria

Qualifiers

Provision of signed and dated informed consent form

Stated willingness and demonstrated ability to comply with all study procedures, as well as availability for the duration of the study

Lives within 100 miles of the NRI study site

Any gender, aged 40-65, inclusive

Disqualifiers

Current diagnosis of any seizure disorder, diabetes or insulin resistance, any kidney or liver disorder, heart disease, anemia, cancer, or Parkinson's disease

ANY chronic illness (pre-disease state acceptable)

Out of range phosphate levels at baseline

BMI less than 25 or greater than or equal to 35

Trial design

Treatments tested in this trial

Niagen®
NAD+
Placebo

Treatment groups

70 Participants

are divided into 9 treatment groups

Treatment groups

See each treatment group below.

Sponsors and collaborators

Nutraceuticals Research Institute

Lead sponsor

ChromaDex, Inc.

Collaborator

Source ClinicalTrials.gov